Tempus AI, Inc. (NASDAQ:TEM) is listed among the 12 Best Genomics Stocks to Invest In. Canaccord reduced its price objective for TEM to $80 from $95, while BofA lowered its estimate from $90 to $80. Both firms expect sector momentum to continue in 2026.

BofA anticipates a rebound in biopharma spending to drive industry growth. Tempus AI provides molecular genotyping and other pathology tests to healthcare professionals, researchers, and pharmaceutical companies. Analysts see potential in TEM but suggest other AI stocks may offer greater upside.

For more investment opportunities, check out 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. No promotional content in the article.

Read more at Yahoo Finance: Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM)